4 ms·
Defense-in-depth, especially at both the beginning and ends of the supply chain. All US pharmacies (retail and otherwise) should be required to capture a random
by sacnoradhq 3y ago
Defense-in-depth, especially at both the beginning and ends of the supply chain. All US pharmacies (retail and otherwise) should be required to capture a random sample of 0.1% of stock to the FDA for comprehensive mass spec characterization processed at federal labs with data released to the public openly. This data must be correlated with complementary point-of-production batch sampling. The data should agree, and would annihilate cheating, scamming, negligent, and incompetent manufacturers from harming patients.
- JoshTko 3y agoThis would be excellent.
- delfinom 3y agoPharmacies in the US are the last place to do it unless the FDA is going to compensate them in full. The shitshow that is the pharmacy supply chain actually puts pharmacies in shitty positions when it comes to drug pricing. Many independent pharmacies actually have to pay the distributor if someone uses one of those discount PBMs like GoodRX. Not to mention some drugs are just obscene at book value for the pharmacy. Instead, pretty much all pharmacies get their drugs from centralized regional distributors. Those distributors should be mandated to take part.